Definitive Healthcare (NASDAQ:DH) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Definitive Healthcare (NASDAQ:DH) issued its quarterly earnings data on Thursday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04), Zacks reports. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. Definitive Healthcare updated its FY 2025 guidance to 0.190-0.220 EPS and its Q1 2025 guidance to 0.020-0.020 EPS.

Definitive Healthcare Stock Performance

Shares of NASDAQ:DH opened at $4.92 on Friday. The firm’s 50 day simple moving average is $4.65 and its 200 day simple moving average is $4.48. Definitive Healthcare has a fifty-two week low of $3.19 and a fifty-two week high of $10.62. The company has a market capitalization of $568.37 million, a price-to-earnings ratio of -1.59, a P/E/G ratio of 4.06 and a beta of 1.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the sale, the insider now directly owns 433,830 shares in the company, valued at $2,039,001. This represents a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 14.84% of the company’s stock.

Analyst Ratings Changes

DH has been the subject of a number of recent research reports. Stephens initiated coverage on Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price for the company. Barclays reissued an “underweight” rating and set a $4.00 price objective on shares of Definitive Healthcare in a report on Monday, January 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Definitive Healthcare currently has an average rating of “Hold” and a consensus price target of $5.72.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.